Pediatric medulloblastoma express immune checkpoint B7-H3
Clin. transl. oncol. (Print)
; 24(6): 1204-1208, junio 2022. ilus
Article
en En
| IBECS
| ID: ibc-203819
Biblioteca responsable:
ES1.1
Ubicación: ES15.1 - BNCS
ABSTRACT
PurposeMedulloblastomas (MB) are highly malignant brain tumors that predominantly occur in young infants. Immunotherapy to boost the immune system is emerging as a novel promising approach, but is often hampered by inhibitory immune checkpoints. In the present study, we have studied immune checkpoint B7-H3 expression in a tissue cohort of human pediatric MB.MethodsExpression of B7-H3 was detected by immunohistochemistry and classified via B7-H3 staining intensity and percentage of B7-H3 positive tumor cells. Subsequently, B7-H3 protein expression was distinguished in MB molecular subtypes and correlated to immune cell infiltrates, patient characteristics, and survival.ResultsB7-H3 protein expression was found in 23 out of 24 (96%) human pediatric MB cases and in 17 out of 24 (71%) MB cases > 25% of tumor cells had any level of B7-H3 expression. B7-H3 protein expression was more frequent on Group-4 MB as compared with other molecular subtypes (p = 0.02). Tumors with high B7-H3 expression showed less influx of γδT cells (p = 0.002) and CD3+ T cells (p = 0.041).ConclusionImmune checkpoint B7-H3 is differentially expressed by the large majority of pediatric MB. This further warrants the development of novel B7-H3-directed (immuno)therapeutic methods for children with incurable, metastatic, or chemo-resistant MB.
Palabras clave
Texto completo:
1
Colección:
06-national
/
ES
Base de datos:
IBECS
Asunto principal:
Neoplasias Encefálicas
/
Neoplasias Cerebelosas
/
Antígenos B7
Límite:
Humans
Idioma:
En
Revista:
Clin. transl. oncol. (Print)
Año:
2022
Tipo del documento:
Article